---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-307134"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2021-10-26T23:59:59+00:00"
generated_at: "2026-06-28T18:05:28.789100+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BridgeBio expands board to 15, appoints Dr. Hannah Valantine as director effective Oct 23, 2021

## Summary
- Board of Directors expanded from 14 to 15 members; Dr. Hannah Valantine appointed as Class I director effective Oct 23, 2021.
- Dr. Valantine received option to purchase $1,200,000 of common stock at $48.45 per share, vesting over three years.
- She currently serves as Professor of Medicine at Stanford and was former Chief Officer for Scientific Workforce Diversity at NIH (2014-2020).
- Dr. Valantine co-invented organ donor-derived cell-free DNA technology for transplant rejection monitoring.
- She also serves on boards of Pacific Biosciences (PACB) and CareDx (CDNA).

## SEC filing metadata
- accession: 0001193125-21-307134
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2021-10-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/0001193125-21-307134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/d164687d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-307134
- JSON: https://secwatch.observer/filing/0001193125-21-307134.json
- Plain text: https://secwatch.observer/filing/0001193125-21-307134.txt

## Key facts
- Executive change
  Dr. Hannah A. Valantine was appointed as Director at BridgeBio Pharma, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/0001193125-21-307134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.